FreeTheAI

Intellia Therapeutics Appoints Jing L. Marantz as Chief Medical Officer

NeutralMedium impact
NTLA$12.58 −3.75%

Intellia Therapeutics, Inc. (NTLA) has appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer. Effective Oct. 26, 2026, Marantz will lead the biotechnology company's translational, development, regulatory, and medical affairs teams. Shares of Intellia Therapeutics were trading down 3.75% at $12.58 following the news.

The leadership update comes at a pivotal time for the company as it advances late-stage clinical programs, including Phase 3 ATTR trials. In her new role, Marantz will oversee approval strategies and trial execution as Intellia prepares for the potential commercial launch of its first in vivo gene editing therapy.

Moving forward, market participants will be tracking how the new medical leadership impacts clinical, regulatory, and launch timelines. Important future catalysts will include Phase 3 trial readouts, regulatory milestone updates, and further details regarding commercialization strategies.

Key points

  • Intellia Therapeutics appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective Oct. 26, 2026.
  • Marantz will lead translational, development, regulatory, and medical affairs during a pivotal late-stage phase.
  • Key priorities include overseeing Phase 3 ATTR trials and preparing for the company's first in vivo gene editing product launch.
  • Shares of Intellia Therapeutics (NTLA) declined 3.75% to $12.58.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Who is the new Chief Medical Officer of Intellia Therapeutics?

Intellia Therapeutics appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective Oct. 26, 2026.

What will Jing L. Marantz focus on at Intellia Therapeutics?

Marantz will lead translational, development, regulatory, and medical affairs, focusing on Phase 3 ATTR trials and preparing for the potential launch of Intellia's first in vivo gene editing therapy.

How did Intellia Therapeutics stock perform?

Intellia Therapeutics, Inc. (NTLA) stock fell 3.75% to $12.58.